These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Imatinib mesylate for melanoma: will a new target be revealed? Grossman D J Invest Dermatol; 2004 Dec; 123(6):xi-xiii. PubMed ID: 15610499 [No Abstract] [Full Text] [Related]
3. Images in pathology. Morphologic features of response to Gleevec (Imatinib) treatment of GIST. Colecchia M; Diment J Int J Surg Pathol; 2003 Apr; 11(2):119. PubMed ID: 12754630 [No Abstract] [Full Text] [Related]
4. Gastrointestinal stromal tumor with metastases in an adult woman treated with imatinib mesylate: MDCT findings. Busalacchi PJ; de la Calle MA; Torroba A; Del Río ST AJR Am J Roentgenol; 2005 Mar; 184(3 Suppl):S58-61. PubMed ID: 15728023 [No Abstract] [Full Text] [Related]
5. Challenges in oncology. Case 4. Response of metastatic gastrointestinal stromal tumor including CNS involvement to imatinib mesylate (STI-571). Brooks BJ; Bani JC; Fletcher CD; Demeteri GD J Clin Oncol; 2002 Feb; 20(3):870-2. PubMed ID: 11821475 [No Abstract] [Full Text] [Related]
6. Imatinib: as adjuvant therapy for gastrointestinal stromal tumor†: profile report. Sanford M; Scott LJ BioDrugs; 2011 Jun; 25(3):191-2. PubMed ID: 21627342 [No Abstract] [Full Text] [Related]
7. Imatinib for chronic myeloid leukaemia: a NICE mess. Barbour V Lancet; 2001 Nov; 358(9292):1478. PubMed ID: 11705557 [No Abstract] [Full Text] [Related]
8. Clinical trials. Keill R Bull Am Coll Surg; 2003 May; 88(5):43. PubMed ID: 23581062 [No Abstract] [Full Text] [Related]
9. David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies. Druker BJ J Clin Oncol; 2003 Dec; 21(23 Suppl):239s-245s. PubMed ID: 14645403 [No Abstract] [Full Text] [Related]
10. Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate. Abhyankar SA; Nair N Clin Nucl Med; 2008 Mar; 33(3):213-4. PubMed ID: 18287851 [No Abstract] [Full Text] [Related]
11. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene. Terheyden P; Houben R; Pajouh P; Thorns C; Zillikens D; Becker JC J Invest Dermatol; 2010 Jan; 130(1):314-6. PubMed ID: 19812602 [No Abstract] [Full Text] [Related]
18. Sunitinib for imatinib-resistant GIST. Joensuu H Lancet; 2006 Oct; 368(9544):1303-4. PubMed ID: 17046443 [No Abstract] [Full Text] [Related]
19. Successful treatment with imatinib in a patient with chronic eosinophilic leukemia not otherwise specified. Iurlo A; Fracchiolla NS; Ferla V; Cassin R; Gottardi E; Beghini A; Gianelli U; Spinelli O; Cortelezzi A J Clin Oncol; 2014 Apr; 32(10):e37-9. PubMed ID: 24449233 [No Abstract] [Full Text] [Related]
20. A new KIT gene mutation in thymic cancer and a promising response to imatinib. Lim SH; Lee JY; Sun JM; Kim KM; Ahn JS; Ahn MJ; Park K J Thorac Oncol; 2013 Oct; 8(10):e91-2. PubMed ID: 24457249 [No Abstract] [Full Text] [Related] [Next] [New Search]